Incidence of Colorectal Cancer in Southwest China: Based on SCC Database

Colorectal Cancer Clinical Trial

Official title:

Incidence of Colorectal Cancer in Southwest China: Based on SCC Database

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06172049
• Other study ID #: CRC-2023
• Status: Completed
• Start date: January 1, 2014
• Est. completion date: October 31, 2023

Study information

• Verified date: December 2023
• Source: West China Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China.

Description:

The epidemiological feature of colorectal cancer (CRC) showed different trends among countries. Studying the epidemiological and management characteristics between China and the US has important implications for understanding the current status of cancer occurrence, treatment and survival. we established the Southwest China Colorectal (SCC) database, aiming to provide reference information on the diagnosis and management of CRC in China.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5838
• Est. completion date: October 31, 2023
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of colorectal cancer;

2. Received treatment in medical institutions;

3. Regular follow-up after the diagnosis.

Exclusion Criteria:

Patients who lost to follow-up

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Other:
• treatment
the actual treatment CRC patients have reveived

Locations

Country	Name	City	State
China	West China Hospital	Chendu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	Overall survival (OS) untile the end of follow up	From inclusion until date of death from any cause, or untile the 2023-10-31